S. Korish

Spebrutinib (CC-292) Affects Markers of B Cell Activation, Chemotaxis, and Osteoclasts in Patients with Rheumatoid Arthritis: Results from a Mechanistic Study

E. Hur, J. Kosek, A. Kivitz, 2019, Rheumatology and Therapy.

SAT0225 Cereblon modulator CC-220 decreases naÏve and memory B cells and plasmacytoid dendritic cells in systemic lupus erythematosus (SLE) patients: exposure-response results from a phase 2A proof of concept study

R. Furie, V. Werth, P. Schafer, 2017 .

Phase 2 Trial of Iberdomide in Systemic Lupus Erythematosus.

T. Dörner, J. Merrill, R. Furie, 2022, The New England journal of medicine.

Biological impact of iberdomide in patients with active systemic lupus erythematosus

P. Lipsky, R. Terbrueggen, T. Dörner, 2022, Annals of the Rheumatic Diseases.

Pomalidomide in Patients with Interstitial Lung Disease due to Systemic Sclerosis: A Phase II, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study

D. Furst, R. Domsic, C. Denton, 2017, The Journal of Rheumatology.

Iberdomide in patients with systemic lupus erythematosus: a randomised, double-blind, placebo-controlled, ascending-dose, phase 2a study

R. Furie, V. Werth, P. Schafer, 2022, Lupus Science & Medicine.

OP0132 EFFECT OF IBERDOMIDE ON CUTANEOUS MANIFESTATIONS IN SYSTEMIC LUPUS ERYTHEMATOSUS: RESULTS OF A 24-WEEK, PLACEBO-CONTROLLED, PHASE 2 STUDY

P. Lipsky, J. Merrill, R. Furie, 2021 .